The Management Team
Detlef Albrecht, M.D., President and Chief Executive Officer
Dr. Albrecht brings two decades of experience in drug development, building companies and executive management. He has led or co-led the development of several products currently on the market, in such diverse areas as urology, oncology, pain management and kidney disease. Dr. Albrecht has been involved in raising more than $180 million in private and public financings. Previously he served as the Chief Medical Officer and Senior Vice President, Research and Development for Relypsa and Ilypsa. Ilypsa was acquired by Amgen in July 2007 for $420 million. Prior he was Vice President of Clinical Development and Member of the Management Board at ALZA Corporation, acquired by Johnson & Johnson in 2001 during his tenure there. He started his industry career in 1992 at Schwarz Pharma in Germany and he holds both medical and doctorate degrees from RWTH Aachen University, Germany.
Howard C. Dittrich, M.D., F.A.C.C., Chief Medical Officer
Dr. Dittrich is a cardiologist by training with more than 20 years of experience in leading clinical research and regulatory affairs at several successful biotechnology companies. Howard co-founded NovaCardia where he served as Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs prior to its acquisition of by Merck & Co. He was responsible for overseeing the clinical and regulatory development of rolofylline for congestive heart failure. From 1996 through 2011, Howard was a clinical professor of medicine at the University of California, San Diego and served as a full-time faculty member from 1984 to 1996. Howard holds a B.S. degree from University of Iowa and an M.D. from the University of Iowa College of Medicine./p>
Linda De Young, PhD, Senior Vice President, Development
Dr. De Young served as the Principal of IND Enabling Consulting, providing project leadership and strategic drug development services for early stage companies. Linda worked with Domain Associates and Sofinnova Ventures portfolio companies, as well as privately funded companies in a broad range of therapeutic areas including small molecule, protein, antisense and cell-based therapies. Previously, Linda was Vice President of Development at Threshold Pharmaceuticals. Prior to Threshold Pharmaceuticals she was Vice President of Development at Angiogenix before which she held scientific positions at AeroGen and Genentech. She received her Ph.D. in Pharmaceutical Chemistry from University of California, San Francisco.
Tom O'Neil, Chief Financial Officer
Mr. O�Neil has over 15 years of finance and operations experience in start-ups through large public companies. Previously, Tom was VP Finance & Administration for Australian publicly-traded ChemGenex Pharmaceuticals prior to its acquisition by Cephalon, Inc. (acquired by Teva Pharmaceuticals). Before ChemGenex, he was VP Finance & Administration for VC-backed biotechnology start-ups, Nodality and HX Diagnostics. Prior to that, Tom held several finance roles at Monogram Biosciences, Inc. (acquired by LabCorp). Tom�s experience includes equity and debt financings, IPO, M&A, collaborations, and investor relations. He has an M.B.A. from the University of California, Los Angeles, Anderson Graduate School of Management, and a B.A. from Pomona College. Tom also provides finance support for two non-profit organizations.
Jason Levin, Chief Business Officer
Mr. Levin brings over 18 years of experience in the biotechnology and pharmaceutical industry. He has been responsible for the consummation of significant strategic transactions across several companies generating more than $500 million in value. Before joining Sorbent, Mr. Levin was responsible for in-licensing, out-licensing and partnering as Chief Business Officer at BrainCells Inc. a neurogenesis based drug discovery and development company in San Diego, CA. Prior to BrainCells, he was Vice President Corporate Development at Jazz Pharmaceuticals, a neurology and psychiatry-focused specialty pharmaceutical company, where he was responsible for licensing, acquisitions, corporate strategy and strategic alliances. Before joining Jazz Pharmaceuticals, Mr. Levin was director of business development at ALZA Corporation, a wholly owned subsidiary of Johnson and Johnson, where he was responsible for both in- and out-licensing of the company’s drug delivery technology. Mr. Levin received an M.B.A. from the University of Texas, McCombs Graduate School of Business, and a Bachelors Degree from the University of California at San Diego. He has been a member of the Licensing Executive Society since 2000.